Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 601–700 of 1,052
HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome
Alcover, S., Ramos-Regalado, L., Girón, G., Muñoz‐García, N., & Vilahur, G. (2025) · Antioxidants · doi:10.3390/antiox14040434 · Cited by 57
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 44
Johansen, M. Ø., Nielsen, S. F., Afzal, S., Vedel‐Krogh, S., Smith, G. D., & Nordestgaard, B. G. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa290 · Cited by 46
Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials
Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0763-0 · Cited by 39
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Picard, F., Bhatt, D. L., Ducrocq, G., Elbez, Y., Ferrari, R., Ford, I., Tardif, J.-C., Tendera, M., Fox, K. M., & Steg, P. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.016 · Cited by 39
Self-citationJin, F., Li, J., Guo, J., Doeppner, T. R., Hermann, D. M., Yao, G., & Dai, Y. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab022 · Cited by 41
Gonzalez, A. L., Dungan, M. M., Smart, C. D., Madhur, M. S., & Doran, A. C. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0284 · Cited by 45
Tseng, P., Zeng, B., Suen, M., Wu, Y., Correll, C. U., Zeng, B., Kuo, J. S., Chen, Y.-W., Chen, T., Tu, Y.-K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.017 · Cited by 40
Kumar, M., Orkaby, A. R., Tighe, C. A., Villareal, D. T., Billingsley, H., Nanna, M. G., Kwak, M. J., Rohant, N., Patel, S., Goyal, P., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100560 · Cited by 55
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management
Patel, N., Mittal, N., Wilkinson, M. J., & Taub, P. R. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100666 · Cited by 47
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
The Evolving Story of Triglycerides and Coronary Heart Disease Risk
Návar, A. M. (2019) · JAMA · doi:10.1001/jama.2018.20044 · Cited by 40
Parikh, M., Raj, P., Austria, J. A., Yu, L., Garg, B., Netticadan, T., & Pierce, G. N. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.06.004 · Cited by 45
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 42
Santos, L. R. B., & Fleming, I. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106407 · Cited by 46
EPA-enriched ethanolamine plasmalogen alleviates atherosclerosis via mediating bile acids metabolism
Ding, L., Zhang, L., Shi, H., Xue, C., Yanagita, T., Zhang, T., & Wang, Y. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103824 · Cited by 41
Zirpoli, H., Chang, C. L., Carpentier, Y., Michael-Titus, A. T., Ten, V. S., & Deckelbaum, R. J. (2020) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124539 · Cited by 42
Chevalier, L., & Plourde, M. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-00767-4 · Cited by 45
Yasuzawa, T., Nakamura, T., Ueshima, S., & Mima, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/2182225 · Cited by 39
Age- and sex-specific trends in the incidence of myocardial infarction in Denmark, 2005 to 2021
Christensen, D. M., Strange, J. E., Phelps, M. D., Schjerning, A. M., Sehested, T. S. G., Gerds, T. A., & Gislason, G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.003 · Cited by 47
Potential of Omega 3 Supplementation for Coronavirus Disease 2019 (COVID-19): A Scoping Review
Fadiyah, N. N., Megawati, G., & Luftimas, D. E. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s357460 · Cited by 44
Wang, Y., Fang, Y., Magliano, D. J., Charchar, F. J., Sobey, C. G., Drummond, G. R., & Golledge, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac124 · Cited by 39
Race-Based and Sex-Based Differences in Bioactive Lipid Mediators after Myocardial Infarction
Halade, G. V., Kain, V., Dillion, C., Beasley, T. M., Dudenbostel, T., Oparil, S., & Limdi, N. A. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12730 · Cited by 38
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
Raygor, V., & Khera, A. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01331-z · Cited by 39
Intersection Between Chronic Kidney Disease and Cardiovascular Disease
Laffin, L. J., & Bakris, G. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01546-8 · Cited by 50
Sajja, A. P., Li, H.-F., Spinelli, K. J., Blumenthal, R. S., Virani, S. S., Martin, S. S., & Gluckman, T. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.042 · Cited by 41
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Lewek, J., & Banach, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01030-w · Cited by 43
Advances in Clinical Imaging of Vascular Inflammation
West, H. W., Dangas, K., & Antoniades, C. A. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.10.007 · Cited by 54
Biosynthesis and Metabolism of ApoB-Containing Lipoproteins
Borén, J., Taskinen, M., & Packard, C. J. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062222-020716 · Cited by 51
Metherel, A. H., Valenzuela, R., Klievik, B. J., Cisbani, G., Rotarescu, R. D., Gonzalez‐Soto, M., Cruciani‐Guglielmacci, C., Layé, S., Magnan, C., Mutch, D. M., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100548 · Cited by 48
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Nutraceutical formulations and natural compounds for the management of chronic diseases
Fatima, G., Khan, S. F., Shukla, V., Al‐Awaida, W., Li, D., & Gushchina, Y. S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1682590 · Cited by 53
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 45
Stanton, A. V., James, K., Brennan, M. M., O’Donovan, F., Buskandar, F., Shortall, K., El-Sayed, T., Kennedy, J., Hayes, H., Fahey, A. G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71801-5 · Cited by 49
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Gaba, P., Bhatt, D. L., Giugliano, R. P., Steg, P. G., Miller, M. J., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.009 · Cited by 38
Self-citationThe year in cardiology 2018: prevention
Reiner, Ž., Laufs, U., Cosentino, F., & Landmesser, U. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy894 · Cited by 49
Mechanistic Insights to Target Atherosclerosis Residual Risk
Alkhalil, M. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.06.004 · Cited by 39
Nagatake, T., Kishino, S., Urano, E., Murakami, H., Kitamura, N., Konishi, K., Ohno, H., Tiwari, P., Morimoto, S., Node, E., et al. (2022) · Mucosal Immunology · doi:10.1038/s41385-021-00477-5 · Cited by 40
Straat, M. E., Jurado‐Fasoli, L., Ying, Z., Nahon, K. J., Janssen, L. G. M., Boon, M. R., Grabner, G. F., Kooijman, S., Zimmermann, R., Giera, M. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104349 · Cited by 40
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
Malick, W. A., Waksman, O., Do, R., Koenig, W., Pradhan, A. D., Stroes, E. S. G., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.034 · Cited by 35
Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 47
Self-citationAdvances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 46
Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study
Chen, G., Qian, Z. M., Zhang, J., Zhang, S., Zhang, Z., Vaughn, M. G., Aaron, H. E., Wang, C., Lip, G. Y. H., & Lin, H. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2022-000451 · Cited by 51
Choi, G. Y., & Calder, P. C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1423228 · Cited by 41
Bioprospecting for Antithrombotic Polar Lipids from Salmon, Herring, and Boarfish By-Products
Τσούπρας, Α., O’Keeffe, E., Lordan, R., Redfern, S., & Zabetakis, I. (2019) · Foods · doi:10.3390/foods8090416 · Cited by 39
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 36
Harris, K., Oshima, M., Sattar, N. A., Würtz, P., Jun, M., Welsh, P. I., Hamet, P., Harrap, S. B., Poulter, N. R., Chalmers, J. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05162-z · Cited by 36
Kita, Y., Watanabe, M., Kamon, D., Ueda, T., Soeda, T., Okayama, S., Ishigami, K., Kawata, H., Horii, M., Inoue, F., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015593 · Cited by 36
Practical Guidance for Food Consumption to Prevent Cardiovascular Disease
Nestel, P. J., Beilin, L. J., Clifton, P. M., Watts, G. F., & Mori, T. A. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.08.022 · Cited by 43
Hernandez, J. D., Li, T., Rau, C. M., LeSuer, W. E., Wang, P., Coletta, D. K., Madura, J. A., Jacobsen, E. A., & Filippis, E. D. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00801-w · Cited by 41
The Relationship Between Nutrition and Atherosclerosis
Wei, T., Liu, J., Zhang, D., Wang, X., Li, G., Ma, R., Chen, G., Lin, X., & Guo, X. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.635504 · Cited by 43
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Myhre, P. L., Kalstad, A. A., Tveit, S. H., Laake, K., Schmidt, E. B., Smith, P., Nilsen, D. W. T., Tveit, A., Solheim, S., Arnesen, H., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13442 · Cited by 38
2022 Taiwan lipid guidelines for primary prevention
Huang, P., Lu, Y., Tsai, Y., Wu, Y., Li, H., Chang, H.-Y., Wu, C., Yang, C., Tarng, D., Huang, C., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.05.010 · Cited by 44
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
Remnant cholesterol is associated with cardiovascular mortality
Zhang, K., Qi, X., Zhu, F., Dong, Q., Gou, Z., Wang, F., Xiao, L., Li, M., Chen, L., Wang, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.984711 · Cited by 42
Santos, H. O., May, T. L., & Bueno, A. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1107475 · Cited by 41
Tybjærg‐Hansen, A., Nordestgaard, B. G., & Christoffersen, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad419 · Cited by 40
Bohula, E. A., Marston, N., Ruzza, A., Murphy, S. A., Ferrari, G. M. D., Díaz, R., Leiter, L. A., Elliott‐Davey, M., Wang, H., Bhatia, A. K., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.004 · Cited by 42
Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Côté, V., Couture, C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad845 · Cited by 37
Slipczuk, L. N., Blankstein, R., Bucciarelli‐Ducci, C., Braun, L. T., Phillips, L. M., Piña, P., Shaw, L. J., Tamis‐Holland, J. E., Williamson, E. E., & Virani, S. S. (2025) · Circulation · doi:10.1161/cir.0000000000001394 · Cited by 47
Zhao, W., Hylton, N. K., Wang, J. P., Chindavong, P. S., Alural, B., Kurtser, I., Subramanian, A., Mazitschek, R., Perlis, R. H., & Haggarty, S. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.006 · Cited by 41
Shen, H. H., Peterson, S. J., Bellner, L., Choudhary, A., Levy, L., Gancz, L., Sasson, A., Trainer, J., Rezzani, R., Resnick, A., et al. (2020) · Antioxidants · doi:10.3390/antiox9060489 · Cited by 40
RetractedYuan, M., Zhang, Y., Hua, T., Liu, X.-L., Liu, T., Yuan, R., Li, G., Zhu, Y., & Zhang, X. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.05.034 · Cited by 40
Simard, M., Rioux, G., Morin, S., Martin, C., Guérin, S. L., Flamand, N., Julien, P., Fradette, J., & Pouliot, R. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.02.755 · Cited by 38
Ishibashi, Y., Goda, H. M., Hamaguchi, R., Sakaguchi, K., Sekiguchi, T., Ishiwata, Y., Okita, Y., 聖也, 持., Ikeuchi, S., Mizobuchi, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02857-w · Cited by 45
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_1 · Cited by 48
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 44
Suzuki, K., Oikawa, T., Nochioka, K., Miura, M., Kasahara, S., Sato, M., Aoyanagi, H., Shiroto, T., Takahashi, J. A., Miyata, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312336 · Cited by 39
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00936-0 · Cited by 34
Maslinic Acid: A New Compound for the Treatment of Multiple Organ Diseases
He, Y., Wang, Y., Yang, K., Jia, J., Zhan, H., Yang, Y., Lv, D., Li, W., & Ding, W. (2022) · Molecules · doi:10.3390/molecules27248732 · Cited by 46
Bäck, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108439 · Cited by 36
Tang, L., Wu, M., Xu, Y., Zhu, T., Fang, C., Ma, K., & Wang, J. (2023) · Inflammation Research · doi:10.1007/s00011-023-01781-5 · Cited by 37
Chen, H., Leng, X., Liu, S., Zeng, Z., Huang, F., Huang, R., Zou, Y., & Xu, Y. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.09.011 · Cited by 36
Gabani, M., Shapiro, M. D., & Toth, P. P. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.16 · Cited by 33
Sekikawa, A. M., Cui, C., Sugiyama, D., Fabio, A., Harris, W. S., & Zhang, X. (2019) · Nutrients · doi:10.3390/nu11112599 · Cited by 42
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
Grevengoed, T. J., Trammell, S. A. J., Svenningsen, J. S., Makarov, M. V., Nielsen, T. S., Jacobsen, J. C., Treebak, J. T., Calder, P. C., Migaud, M. E., Cravatt, B. F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143861 · Cited by 33
Saadatagah, S., Pasha, A. K., Alhalabi, L., Sandhyavenu, H., Farwati, M., Smith, C. Y., Wood‐Wentz, C. M., Bailey, K. R., & Kullo, I. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019343 · Cited by 37
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Rabbat, M. G., Lakshmanan, S., Benjamin, M. M., Doros, G., Kinninger, A., Budoff, M. J., & Bhatt, D. L. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead063 · Cited by 34
Self-citationOmega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 48
Foundational Nutrition: Implications for Human Health
Townsend, J. R., Kirby, T. O., Marshall, T. M., Church, D. D., Jajtner, A. R., & Esposito, R. (2023) · Nutrients · doi:10.3390/nu15132837 · Cited by 53
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 40
Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates
Maki, K. C., & Dicklin, M. R. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000537 · Cited by 36
Costenbader, K. H., MacFarlane, L. A., Lee, I.-M. M., Buring, J. E., Mora, S., Bubes, V. Y., Kotler, G., Camargo, C. A., Manson, J. E., & Cook, N. R. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.306902 · Cited by 37
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
Self-citationAre dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
Sherratt, S. C. R., Lero, M., & Mason, R. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000665 · Cited by 33
Colhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0991-1 · Cited by 33
Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling
del Campo, L. S. D., Rodrigues‐Díez, R., Salaíces, M., Briones, A. M., & García‐Redondo, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073592 · Cited by 39
Differentiating EPA from EPA/DHA in cardiovascular risk reduction
Toth, P. P., Chapman, M. J., Parhofer, K. G., & Nelson, J. R. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100148 · Cited by 33
“Contemporary CV outcomes trials using omega-3 fatty acids are summarized in Table 2 [17,24 – 27].”
BackgroundMethodInfluentialSergi, D., Spaggiari, R., Nora, E. D., Angelini, S., Castaldo, F., Omenetto, A., Stifani, G., Sanz, J. M., & Passaro, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112103 · Cited by 37
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms
Cuenoud, B. M., Rochat, I., Gosoniu, M., Dupuis, L., Berk, E. S., Jaudszus, A., Mainz, J. G., Hafen, G., Beaumont, M., & Cruz‐Hernandez, C. (2020) · Nutrients · doi:10.3390/nu12041014 · Cited by 40
Lombardi, M., Chiabrando, J. G., Vescovo, G. M., Bressi, E., Del Buono, M. G., Carbone, S., Koenig, R. A., Van Tassell, B. W., Abbate, A., Biondi-Zoccai, G., et al. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00865-5 · Cited by 33
Fluorescent nanocarriers targeting VCAM-1 for early detection of senescent endothelial cells
Belcastro, E., Rehman, A. U., Remila, L., Park, S., Gong, D., Anton, N., Auger, C., Lefèbvre, O., Goetz, J. G., Collot, M., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102379 · Cited by 40
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
Wilkins, J. T., & Lloyd‐Jones, D. M. (2021) · JAMA · doi:10.1001/jama.2021.2244 · Cited by 33
Yamagata, K. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106704 · Cited by 37
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.